{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:48:54Z","timestamp":1782737334537,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00108-026-02096-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:01:38Z","timestamp":1773244898000},"page":"827-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiinflammatorische Therapiestrategien bei koronarer Herzkrankheit","Anti-inflammatory treatment strategies in coronary heart disease"],"prefix":"10.1007","volume":"67","author":[{"given":"Ulrich","family":"Hofmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","volume":"46","author":"MA D\u2019entremont","year":"2025","unstructured":"D\u2019entremont\u00a0MA, Poorthuis\u00a0MHF, Fiolet\u00a0ATL et\u00a0al (2025) Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J 46:2564\u20132575","journal-title":"Eur Heart J"},{"key":"2096_CR2","volume":"11","author":"F Ebrahimi","year":"2025","unstructured":"Ebrahimi\u00a0F, Ebrahimi\u00a0R, Beer\u00a0M et\u00a0al (2025) Colchicine for the secondary prevention of cardiovascular events. Cochrane Database Syst Rev 11:CD014808","journal-title":"Cochrane Database Syst Rev"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett\u00a0BM, Cornel\u00a0JH, Lainscak\u00a0M et\u00a0al (2019) Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation 139:1289\u20131299","journal-title":"Circulation"},{"key":"2096_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly\u00a0SS, D\u2019entremont\u00a0MA, Lee\u00a0SF et\u00a0al (2025) Colchicine in Acute Myocardial Infarction. N Engl J Med 392:633\u2013642","journal-title":"N Engl J Med"},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","volume":"144","author":"N Mewton","year":"2021","unstructured":"Mewton\u00a0N, Roubille\u00a0F, Bresson\u00a0D et\u00a0al (2021) Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation 144:859\u2013869","journal-title":"Circulation"},{"key":"2096_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf\u00a0SM, Fiolet\u00a0ATL, Mosterd\u00a0A et\u00a0al (2020) Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 383:1838\u20131847","journal-title":"N Engl J Med"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker\u00a0PM (2016) Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 37:1720\u20131722","journal-title":"Eur Heart J"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Pradhan\u00a0A et\u00a0al (2019) Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 380:752\u2013762","journal-title":"N Engl J Med"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Thuren\u00a0T et\u00a0al (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif\u00a0JC, Kouz\u00a0S, Waters\u00a0DD et\u00a0al (2019) Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 381:2497\u20132505","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02096-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02096-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:28:20Z","timestamp":1782736100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02096-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02096-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"27 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U. Hofmann hat Honorare f\u00fcr Beratungsleistungen oder Vortr\u00e4ge von den in dem Zusammenhang relevanten Arzneimittelherstellern Apontis, Novartis und Novo Nordisk erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}